Liquidia (NASDAQ:LQDA) Director Acquires $317,894.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Caligan Partners Lp bought 5,300 shares of Liquidia stock in a transaction dated Tuesday, May 19th. The stock was purchased at an average price of $59.98 per share, for a total transaction of $317,894.00. Following the purchase, the director directly owned 8,138,951 shares in the company, valued at $488,174,280.98. This represents a 0.07% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Liquidia Stock Down 1.6%

Shares of NASDAQ:LQDA opened at $60.98 on Friday. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $62.30. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The company’s fifty day moving average is $42.06 and its 200-day moving average is $37.24. The company has a market capitalization of $5.42 billion, a PE ratio of 435.60 and a beta of 0.41.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The company’s quarterly revenue was up 4187.1% compared to the same quarter last year. Equities research analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LQDA. Farallon Capital Management LLC raised its holdings in shares of Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares during the last quarter. TCG Crossover Management LLC bought a new position in shares of Liquidia in the third quarter valued at about $38,887,000. Caprock Group LLC bought a new position in shares of Liquidia in the third quarter valued at about $37,114,000. MPM Bioimpact LLC raised its holdings in shares of Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after buying an additional 1,200,869 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new position in shares of Liquidia in the third quarter valued at about $12,571,000. 64.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LQDA has been the topic of several recent analyst reports. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. BTIG Research boosted their target price on shares of Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Oppenheimer lifted their price target on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a report on Thursday, March 12th. Finally, HC Wainwright lifted their price target on Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $49.33.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).